Home/Peptides/YourProtocol/Ipamorelin: Evidence, Legal Status, and Safety

Ipamorelin: Evidence, Legal Status, and Safety

Ipamorelin is a growth-hormone secretagogue that works through the ghrelin receptor, often stacked with CJC-1295. No completed human RCTs support its popular recovery, fat-loss, or anti-aging uses. It is not FDA-approved, reportedly on the FDA's restricted-compounding list pending review, and banned at all times under WADA's anti-doping code.

Research chemical; banned in sport (WADA)
Hormones
In-house · synthesized from the cited primary sources
At a glance
Time
5 min
Sources
1
No completed human RCTs for ipamorelin's popular use case, recovery, fat loss, or anti-aging, were found; it is not an FDA-reviewed drug.
What the evidence says
What it is
Understand the mechanism A growth-hormone secretagogue that works through the ghrelin receptor (a “GH-releasing peptide”), a different pathway from GHRH analogs like CJC-1295 or tesamorelin, and often stacked with CJC-1295 to combine two GH-release pathways.

Combining two different receptor pathways is the marketing logic behind the “CJC-1295 plus ipamorelin” stack.

Research synthesis of GH-secretagogue peptides, 2026
Evidence tier: C
See what the human evidence actually is No completed human RCTs for ipamorelin's popular uses, recovery, fat loss, anti-aging, were found. It is not an FDA-reviewed drug.

Popularity as a “stack” ingredient does not substitute for trial evidence.

Research synthesis, 2026
Legal status
Know where it actually stands Not FDA-approved for any use. Reported on the FDA's 503A Category 2 restricted-compounding list as of April 2026, and reported as one of five peptides in the FDA's formal review process. Banned at all times under WADA's S2 category.

Same reported status class as CJC-1295: under formal review, not approved.

FDA 503A Category 2 reporting; WADA S2 list
Safety
Know the real risk Same GH-secretagogue class-effect caveats as CJC-1295: hunger and ghrelin increase, prolactin elevation, and REM-sleep disruption are flagged for this compound class. Unregulated-sourcing purity risk applies as with the rest of the gray market.

These are class-wide, expert-flagged effects, not isolated anecdotes.

Huberman Lab peptide-therapeutics episode
The evidence 1

No completed human RCTs for ipamorelin's popular use case, recovery, fat loss, or anti-aging, were found; it is not an FDA-reviewed drug.

View sources
Huberman Lab: Benefits & Risks of Peptide Therapeutics for Physical & Mental Health (GH-secretagogue class segment) Read hubermanlab.com

Not medical advice. This page is for education only and is not a substitute for professional medical care. Consult a qualified clinician before changing your health routine.
Editorial disclosure. This protocol is written and fact-checked by the YourProtocol editorial team directly from the primary sources cited below; it is not written or reviewed by any outside expert.

Is this for you
  • Anyone considering ipamorelin who wants the honest evidence before discussing it with a clinician
  • Athletes checking WADA and anti-doping status
  • Readers who have seen the “CJC-1295 plus ipamorelin” stack marketed and want the actual evidence
  • Readers comparing GH secretagogues to FDA-approved GH-axis drugs like tesamorelin
Cautions
  • Not FDA-approved for any use; reported on the FDA's restricted-compounding list pending formal review.
  • Banned at all times under WADA's anti-doping code (S2); can result in a competition ban if detected.
  • No completed human RCT establishes its safety or efficacy for the popular use case.
  • Educational only, not medical advice.
Common questions
Is ipamorelin legal?
It is not FDA-approved for any use and is reported on the FDA's 503A Category 2 restricted-compounding list as of April 2026, pending formal review. It is also banned at all times for competitive athletes under WADA's code.
Why is ipamorelin often stacked with CJC-1295?
The two work through different mechanisms, CJC-1295 through the GHRH receptor and ipamorelin through the ghrelin receptor, and are marketed together to combine two GH-release pathways. No completed human RCT has evaluated that combination's safety or efficacy.
What are the known risks of GH-secretagogue peptides like ipamorelin?
Andrew Huberman flags hunger and ghrelin increase, prolactin elevation, and REM-sleep disruption as class-wide effects for GH secretagogues including ipamorelin.
Get the next protocol first
Evidence updates, cited to the source. No spam.